These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 27462719

  • 1. Parameters of Predictive Value in Chronic Myeloid Leukemia-The Prognostic Impact of Histopathological Variables in a Multivariate Regression Analysis.
    Thiele J, Kvasnicka HM, Zankovich R, Fischer R, Diehl V.
    Leuk Lymphoma; 1991; 4(1):63-74. PubMed ID: 27462719
    [Abstract] [Full Text] [Related]

  • 2. Histological features of prognostic significance in CML--an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow.
    Thiele J, Kvasnicka HM, Titius BR, Parpert U, Nebel R, Zankovich R, Dienemann D, Stein H, Diehl V, Fischer R.
    Ann Hematol; 1993 Jun; 66(6):291-302. PubMed ID: 8318559
    [Abstract] [Full Text] [Related]

  • 3. A histomorphometric analysis of trephine biopsies of bone marrow from 65 patients with chronic myeloid leukemia. Classification of patients into subgroups with different survival patterns.
    Thiele J, Wienhold S, Zankovich R, Fischer R.
    Anal Quant Cytol Histol; 1990 Apr; 12(2):103-16. PubMed ID: 2350386
    [Abstract] [Full Text] [Related]

  • 4. [Prognostic analysis of chronic myeloid leukemia with Cox model and the Sokal, Hasford score].
    Gan DY, Chen Y.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):662-6. PubMed ID: 16928295
    [Abstract] [Full Text] [Related]

  • 5. Prognostic features at diagnosis of chronic myeloid leukaemia with special emphasis on histological parameters.
    Thiele J, Thienel C, Zankovich R, Fischer R.
    Med Oncol Tumor Pharmacother; 1988 Aug; 5(1):49-60. PubMed ID: 3163405
    [Abstract] [Full Text] [Related]

  • 6. [Multivariate analysis of prognostic factors influencing survival in chronic myelogenous leukemia].
    Sakamoto S, Kurata H, Miwa A.
    Rinsho Ketsueki; 1989 Aug; 30(8):1180-4. PubMed ID: 2601030
    [Abstract] [Full Text] [Related]

  • 7. Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial.
    Kvasnicka HM, Thiele J, Schmitt-Graeff A, Diehl V, Zankovich R, Niederle N, Leder LD, Schaefer HE.
    J Clin Oncol; 2001 Jun 15; 19(12):2994-3009. PubMed ID: 11408494
    [Abstract] [Full Text] [Related]

  • 8. Clinical and histological features retain their prognostic impact under interferon therapy of CML: a pilot study.
    Thiele J, Kvasnicka HM, Niederle N, Kloke O, Schmidt M, Lienhard H, Zirbes T, Meuter RB, Leder LD, Fischer R.
    Am J Hematol; 1995 Sep 15; 50(1):30-9. PubMed ID: 7545352
    [Abstract] [Full Text] [Related]

  • 9. Variables influencing the timing of marrow transplantation in patients with chronic myelogenous leukemia.
    Segel GB, Simon W, Lichtman MA.
    Blood; 1986 Nov 15; 68(5):1055-64. PubMed ID: 3533178
    [Abstract] [Full Text] [Related]

  • 10. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ben Lakhal R, Ghedira H, Bellaaj H, Ben Youssef Y, Menif S, Manai Z, Bedoui M, Lakhal A, M'Sadek F, Elloumi M, Khélif A, Ben Romdhane N, Laatiri MA, Ben Othmen T, Meddeb B.
    Ann Hematol; 2018 Apr 15; 97(4):597-604. PubMed ID: 29305630
    [Abstract] [Full Text] [Related]

  • 11. Impact of clinical and morphological variables in classification and regression tree-based survival (CART) analysis of CML with special emphasis on dynamic features.
    Thiele J, Kvasnicka HM, Zirbes TK, Flucke U, Niederle N, Leder LD, Diehl V, Fischer R.
    Eur J Haematol; 1998 Jan 15; 60(1):35-46. PubMed ID: 9451426
    [Abstract] [Full Text] [Related]

  • 12. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
    Steegmann JL, Odriozola J, Rodriguez-Salvanés F, Giraldo P, García-Laraña J, Ferro MT, Benítez E, Pérez-Pons C, Giralt M, Escribano L, Lavilla E, Miguel A, Areal C, Pérez-Encinas M, Abad A, Maldonado J, Massagué I, Fernández-Rañada JM.
    Haematologica; 1999 Nov 15; 84(11):978-87. PubMed ID: 10553157
    [Abstract] [Full Text] [Related]

  • 13. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
    Kanakasetty GB, Thanky AH, Kuntegowdanahalli L, Dasappa L, Jacob L, Mallekavu SB, Lakkavalli R, Kadabur L, Antapura R.
    Clin Lymphoma Myeloma Leuk; 2017 Jun 15; 17(6):375-381. PubMed ID: 28502460
    [Abstract] [Full Text] [Related]

  • 14. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE.
    Cancer; 2017 Nov 15; 123(22):4391-4402. PubMed ID: 28743165
    [Abstract] [Full Text] [Related]

  • 15. The prognostic implication of clinical and histological features in Ph1+ chronic myelocytic leukaemia (CML).
    Thiele J, Fohlmeister I, Vonneguth B, Zankovich R, Fischer R.
    Anticancer Res; 1986 Nov 15; 6(6):1401-9. PubMed ID: 3468880
    [Abstract] [Full Text] [Related]

  • 16. Risk Stratification of Chronic Myeloid Leukemia According to Different Prognostic Scores.
    Aijaz J, Junaid N, Asif Naveed M, Maab R.
    Cureus; 2020 Mar 20; 12(3):e7342. PubMed ID: 32313783
    [Abstract] [Full Text] [Related]

  • 17. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
    Uz B, Buyukasik Y, Atay H, Kelkitli E, Turgut M, Bektas O, Eliacik E, Isik A, Aksu S, Goker H, Sayinalp N, Ozcebe OI, Haznedaroglu IC.
    Hematology; 2013 Sep 20; 18(5):247-52. PubMed ID: 23540886
    [Abstract] [Full Text] [Related]

  • 18. Primary myelofibrosis-osteomyelosclerosis (agnogenic myeloid metaplasia): correlation of clinical findings with bone marrow histopathology and prognosis.
    Thiele J, Steinberg T, Zankovich R, Fischer R.
    Anticancer Res; 1989 Sep 20; 9(2):429-35. PubMed ID: 2751268
    [Abstract] [Full Text] [Related]

  • 19. Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study.
    Korkolopoulou P, Viniou N, Kavantzas N, Patsouris E, Thymara I, Pavlopoulos PM, Terpos E, Stamatopoulos K, Plata E, Anargyrou K, Androulaki A, Davaris P, Yataganas X.
    Leukemia; 2003 Jan 20; 17(1):89-97. PubMed ID: 12529665
    [Abstract] [Full Text] [Related]

  • 20. Bone marrow histopathology in chronic myelogenous leukemia (CML)--evaluation of distinctive features with clinical impact.
    Thiele J, Kvasnicka HM, Fischer R.
    Histol Histopathol; 1999 Oct 20; 14(4):1241-56. PubMed ID: 10506940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.